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 approaches for subsyndromal mood symptoms. However, 
when measured in both naturalistic studies and clinical
trials, subsyndromal mood symptoms were frequently re-
ported by patients receiving maintenance therapy and were 
associated with poor functioning. As with other chronic 
 illnesses, knowledge of the patient’s perspective of daily 
morbidity is important for improving the clinical outcome. 
Studies of maintenance therapy for bipolar disorder, regard-
less of the approach, should measure subsyndromal mood 
symptoms as an additional outcome. 
 Copyright © 2009 S. Karger AG, Basel 
 Introduction 
 It has long been observed that patients with bipolar 
disorder commonly experience symptoms that do not 
meet the DSM-IV diagnostic criteria for an episode  [1–7] . 
When we investigated the impact of decreasing the min-
imum episode length requirement to 2 days using daily 
self-reported data, the number of depressed episodes for 
all patients quadrupled and the number of hypomanic 
episodes tripled  [8, 9] . The frequent occurrence of sub-
syndromal symptoms has also been noted in other longi-
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 Abstract 
 Objective: To explore the measurement of subsyndromal 
mood symptoms in relation to studies of maintenance ther-
apy for bipolar disorder.  Methods: Literature review of the 
Medline database using the following selection criteria: (1) 
‘bipolar disorder’ plus ‘inter-episode or interepisode or sub-
syndromal or subclinical or residual or subthreshold’ and (2) 
‘bipolar disorder’ plus ‘maintenance or prophylaxis or longi-
tudinal’. Studies of children or adolescents and non-English-
language reports were excluded.  Results: Of the studies 
published between 1987 and October 2007, 77 articles about 
subsyndromal mood symptoms and 257 studies of mainte-
nance therapy agents were found. Only 11 of the 257 studies 
of maintenance therapy agents discussed subsyndromal 
mood symptoms. Of the 77 articles, two thirds were pub-
lished after 2000. Inconsistent definitions of subsyndromal 
mood symptoms and different evaluation tools and meth-
odologies were used in the studies.  Conclusions: There is
a need to standardize definitions and validate measuring 
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tudinal studies by either self-report  [10] or clinician rat-
ings  [11–16] and in 2 randomized, placebo-controlled tri-
als of maintenance therapies by clinician ratings  [17] . 
Furthermore, subsyndromal symptoms were frequently 
present in a cross-sectional study of patients who were in 
clinical remission  [18] . Subsyndromal symptoms have 
been associated with significant functional disability 
 [19–28] and with an increased risk of relapse  [24, 29–33] . 
These subsyndromal mood symptoms persist despite the 
range of pharmacotherapies now available for treating bi-
polar disorder, and several researchers have noted the 
need for increased recognition of their clinical signifi-
cance  [5, 6, 15, 28, 34–39] . The purpose of this limited 
review is to examine the current usage and potential con-
tribution of the measurement of subsyndromal mood 
symptoms to studies of maintenance therapies for bipolar 
disorder.
 Methods 
 The published literature was searched using the Medline da-
tabase with selection criteria of ‘bipolar disorder’ plus ‘inter-epi-
sode or interepisode or subsyndromal or subclinical or residual 
or subthreshold’. This was supplemented by manual searches of 
relevant cross-referenced articles. To find all the maintenance 
drug studies conducted during the same time period, a second 
search using ‘bipolar disorder’ plus ‘maintenance or prophylaxis 
or longitudinal’ was completed. Both open and controlled trials 
of maintenance therapies were included. Articles about children 
or adolescents were excluded. Only English-language publica-
tions were included.
 Results 
 Type and Number of Articles Found 
 Seventy-seven articles on subsyndromal mood symp-
toms that were published between 1987 and October 2007 
were identified. Of the 77 articles, 24 (31%) were pub-
lished before the year 2000 and 53 (69%) after the year 
2000. The distribution of article type for these 77 articles 
is shown in  figure 1 , with the greatest number of articles 
(34; 44%) being about the course of illness. For the same 
time period, between 1987 and October 2007, 257 studies 
of maintenance therapy agents were found. Only 11 of the 
257 discussed subsyndromal symptoms, and 8 of these 11 
studies involved lithium.
 Definition and Measurement of Subsyndromal Mood 
Symptoms 
 In the 77 articles, no common definition of subsyn-
dromal mood symptoms was used. Examples of these 
definitions include mood symptoms of minor severity 
 [15] , symptoms that meet some but not all the DSM-IV 
criteria and last for the standard episode length  [27] , 
symptoms that meet the DSM-IV criteria for severity but 
not for episode length  [8, 9, 24] and symptoms less severe 
than hypomania or minor depression  [3, 5, 6, 11, 12] . Fur-
thermore, each study used a unique methodological ap-
proach to measuring subsyndromal mood symptoms, in-
volving diverse instruments and time intervals between 
measurements ( table 1 ). All studies were included in the 
analysis regardless of definition or methodology.
 Review and Discussion 
 Frequent Subsyndromal Symptoms 
 Although there is no standard definition of subsyn-
dromal mood symptoms and evaluation approaches dif-
fer, subsyndromal mood symptoms were detected in ev-
ery longitudinal study that measured them  [1, 4, 8–17, 19, 
23, 26, 27, 29, 30, 34, 38, 40, 41] . Several recent longitudi-
nal studies lasting over a year have reported that patients 
with bipolar disorder spent about half the time ill, pre-
dominantly with subsyndromal symptoms  [12, 13, 15, 
38] . Subsyndromal depressive symptoms predominate 
over subsyndromal manic symptoms  [7, 9, 11–13, 16, 17, 
42, 43] , and the frequency of subsyndromal depressive 
symptoms does not differ between bipolar I and bipolar 
II disorders  [9, 16] . Furthermore, symptoms of depression 
that occur outside of an episode may at times be severe in 
intensity  [9] . Up to 70% of patients with bipolar disorder 
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 Fig. 1. Distribution of types of articles on subsyndromal mood 
symptoms published between 1987 and October 2007. 
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experience interepisode symptoms  [30, 44] , and these are 
not a phenomenon only of the sickest patients, when de-
fined as those experiencing an episode that meets the 
DSM-IV criteria at some point during the study period. 
Subsyndromal symptoms of both depression and hypo-
mania also occurred frequently in patients who did not 
meet the criteria for a DSM-IV episode during the study 
period  [8, 9] . In the post hoc analysis of 2 placebo-con-
trolled maintenance trials, the median time to the onset 
of subsyndromal symptoms in patients stabilized on lith-
ium or lamotrigine was just 15 days  [17] .
 Subsyndromal Symptoms and Outcome 
 Ongoing subsyndromal symptoms may have a strong-
ly negative impact on every aspect of life for patients with 
bipolar disorder. Multiple researchers have reported that 
subsyndromal symptoms are associated with a poor func-
tional outcome, including high levels of unemployment, 
underemployment or inability to complete home duties 
 [19, 21, 23, 24, 27, 28] , impairment of social adjustment 
that impacts on family life, interpersonal relationships 
and social activities  [20, 26–28] , and low self-esteem  [22] . 
The presence of subsyndromal symptoms also increases 
the risk of relapse into episodes of mania or depression 
 [29–32] .
 Other Subsyndromal Symptoms 
 Other morbidity that is associated with bipolar disor-
der may contribute to the daily level of subsyndromal 
mood symptoms, especially of depression  [39] . Cognitive 
impairments that persist after the resolution of episodic 
mood symptoms have been detected across a range of 
tasks of attention, memory and executive function  [45–
47] and are associated with low psychosocial functioning 
Table 1. Examples of instruments used to measure subsyndromal mood symptoms
Study Number
of patients
Study length Instrument Measurement
frequency
Rater
Altshuler
et al. [27]
759 several years Inventory of Depressive Symptomatology- 
Clinician Rated [80]
2 weeks clinician
Frye et al. [17] 575
originally
2 pooled
18-month trials
Hamilton Rating Scale for Depression-17 
and Mania Rating Scale from the Schedule 
for Affective Disorders and Schizophrenia-
Change Version [81] 
weekly, biweekly,
monthly, per protocol
clinician
Paykel et al. [15] 204 18 months Longitudinal Interval Follow-up
Evaluation [82]
weekly clinician
MacQueen
et al. [24]
138 1 year modified NIMH Life Chart method daily clinician
Judd et al. [11] 146 13 years Longitudinal Interval Follow-up Evaluation weekly clinician
Angst et al. [1] 591 15 years Structured Psychopathological Interview 
and Rating of the Social Consequences for 
Epidemiology [83]
yearly questionnaire;
4 interviews in total
clinician
Bauer et al. [8, 9] 203 5 months ChronoRecord software [75, 76] daily self-report
Kupka
et al. [14, 16]
539 1 year NIMH Life Chart methodology daily self-report;
clinician
adjusted
Calabrese
et al. [43]
593 1 year Mood Disorder Questionnaire [84] survey of prior
4 weeks and prior year
self-report
Denicoff et al. [10] 30 2 years NIMH Life Chart Methodology-p twice daily self-report
NIMH = National Institute of Mental Health.
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 [33, 48] and subsyndromal mood symptoms  [49] . Sleep 
disturbances including insomnia are frequently reported 
in patients in remission from acute episodes  [50] . Side ef-
fects of medications routinely used to treat bipolar disor-
der may negatively impact cognitive functioning  [51] and 
cause sedation or fatigue. Furthermore, the high rates of 
comorbidities associated with bipolar disorder, including 
substance abuse, anxiety disorders and eating disorders, 
may intensify the subsyndromal symptoms  [24, 37, 52] . 
Patient nonadherence with treatments may also contrib-
ute to subsyndromal symptoms.
 Clinical Trials of Maintenance Agents for Bipolar 
Disorder 
 Diverse factors may contribute to the unexpected sub-
syndromal load present in many patients receiving main-
tenance treatment for bipolar disorder. Although recogni-
tion of their importance is increasing, subsyndromal 
mood symptoms are not routinely measured during stud-
ies of maintenance therapy for bipolar disorder. The prin-
cipal method used to determine drug efficacy is random-
ized clinical trials in which a predetermined primary out-
come parameter is measured in all study participants to 
detect the response to treatment. In clinical trials of agents 
for either acute or maintenance treatment of bipolar dis-
order, the primary outcome is defined clinically, using 
physician-observed events such as the time until an inter-
vention  [53] or episode recurrence  [54] . These events are 
intermediate end points, defined as a measure that is of 
genuine clinical benefit, but is not the ultimate end point 
of the disease such as survival  [55] . Intermediate end 
points are regularly used as the basis for Food and Drug 
Administration (FDA) marketing approval, although im-
provement in an intermediate end point may not result in 
reduced morbidity or mortality  [55] . While the value of 
the events used to determine efficacy for maintenance 
treatment of bipolar disorder is unquestionable, it appears 
that these intermediate end points may not translate di-
rectly into improvements in daily morbidity as defined by 
subsyndromal mood symptom levels. Furthermore, the 
sample size during clinical trials of efficacy is designed to 
measure and detect a significant difference in the prima-
ry outcome and not the daily symptom load.
 The relationship between subsyndromal symptoms 
and the time to relapse may not be the same for all med-
ications  [17] . Bipolar disorder is a complex, heterogeneous 
disease with a significant genetic component. The vari-
ability in effectiveness and suppression of subsyndromal 
symptoms may define subtypes of the disorder or reflect 
genetic polymorphisms in disease pathways or drug me-
tabolism  [56] . As proposed for nonpsychiatric illnesses 
with unclear pathophysiology, some maintenance agents 
may only influence a portion of a complex disease process 
or may act through an unintended, independent mecha-
nism of action  [57, 58] . Lastly, the issues relating to effi-
cacy studies and the apparent overestimation of the ef-
fectiveness of medications in clinical practice have been 
well documented  [59, 60] .
 Specific Treatment of Subsyndromal Mood Symptoms 
 There are few articles regarding the specific treatment 
of subsyndromal mood symptoms, and measures gener-
ally follow the established practice guidelines for the 
treatment of a major relapse, although there is limited 
evidence that increasing the dosage of lithium  [30, 61] or 
an anticonvulsant  [62] may be useful. In clinical practice, 
multiple psychotropic drugs are routinely prescribed, in 
part as an attempt to improve control over subsyndromal 
symptoms. Psychoeducation techniques, when used as 
adjuvants to pharmacological treatments, may help to re-
duce interepisode symptoms  [63–66] . In the future, bio-
markers may be used to measure residual disease.
 Subsyndromal Mood Symptoms and Chronicity 
 The importance of subsyndromal mood symptoms in-
creases after the high symptom load present during an 
acute episode is stabilized and the disease becomes chron-
ic. However, since the efficacy of most maintenance ther-
apies has been established for acute mania or depression, 
patients who meet the DSM-IV criteria for an episode may 
derive more benefit than those whose current problems 
are due to subsyndromal mood symptoms. Moreover, the 
common occurrence of subsyndromal symptoms sug-
gests that the response to an agent during the acute epi-
sode may not always predict the patients with the best 
functional outcome or the success of maintenance thera-
py with the same agent. Unless subsyndromal symptoms 
can be reduced to a level tolerable to the patient, the same 
agent that seemed invaluable when treating the dramatic 
symptoms of the acute episode may seem to be ineffective 
over time. Furthermore, since symptoms fluctuate rap-
idly in the natural course of bipolar disorder  [67, 68] , if the 
commonly used maintenance agents have only a modest 
impact on the daily symptom load, it may be difficult to 
distinguish the effects of chronic treatment from the nat-
ural fluctuations in the disease.
 Measuring Patient Perception of Disease 
 The high frequency of subsyndromal mood symptoms 
and associated functional impairment implies that pa-
 Subsyndromal Symptoms and Bipolar 
Maintenance 
 Psychopathology 2010;43:1–7 5
tient well-being is not solely determined by the presence 
or absence of episodes that meet the DSM-IV criteria. In-
deed, it is not unusual for patient perception of disease 
burden to be at variance with clinician ratings, since 
there is only a weak correlation between objective or cli-
nician measures and patient reports of functional limita-
tions in a variety of chronic conditions such as chronic 
obstructive pulmonary disease, low-back pain, rheuma-
toid arthritis and stroke  [69] . Therefore, as in other chron-
ic illnesses where prevention and control rather than cure 
is the aim of therapy, it is important to obtain the patient’s 
perspective on their daily functioning and well-being 
 [69] . The need for the patient perspective has been recog-
nized by the regulators with the recent FDA release of a 
draft guidance regarding the use of patient-reported out-
comes (PRO) as a new outcomes classification  [70] . Vali-
dated PRO instruments can provide unique measures 
that are complementary to traditional clinician measures 
of efficacy  [70] . Of the 215 prescription-only new drugs 
approved by the FDA between 1997 and 2002, 23 drugs, 
primarily antimigraine drugs and antiepileptics, relied 
solely on PRO end points for approval, while another 41 
drugs for a range of chronic conditions such as Parkin-
son’s disease, rheumatoid arthritis, asthma and allergies 
included PRO along with traditional end points  [71] .
 There is a need to incorporate measurement of sub-
syndromal symptoms and the patient perspective of life 
quality into future maintenance studies of bipolar disor-
der, regardless of whether the study has an efficacy, ef-
fectiveness or hybrid design. However, since patients with 
hypomania may lack insight, self-reported data must be 
interpreted with care and should supplement but not re-
place clinician findings. In the future, as with other 
chronic conditions, achieving an acceptably low daily 
burden of symptoms in bipolar disorder may become as 
important a goal for long-term stability as is the recovery 
from an acute episode  [72] .
 Several validated tools are available to measure daily 
mood symptom load in bipolar disorder, including the 
National Institute of Mental Health Life Chart using pa-
per  [10] or a palmtop computer  [73] , the ChronoSheet us-
ing paper  [74] or the ChronoRecord software for a per-
sonal computer  [75, 76] . There are also several instru-
ments to measure quality of life in patients with bipolar 
disorder, as reviewed elsewhere  [77] . Detailed investiga-
tions are also required to understand the frequency, du-
ration and severity of subsyndromal symptoms that are 
tolerable to most patients with bipolar disorder and the 
impact of treatment of subsyndromal symptoms on long-
term outcome. A useful approach to the study of new 
medications may be to determine if they reduce the bur-
den of subsyndromal symptoms when used as adjunctive 
agents, similar to the methodology used for anticonvul-
sants in epilepsy  [78] .
 Limitations 
 Only the Medline database was searched. The number 
of studies of subsyndromal mood symptoms was small, 
and these contained inconsistencies in definitions, mea-
surements and study design. Subsyndromal symptoms 
other than mood-related symptoms were included in 
some studies. Furthermore, the frequency and pattern of 
subsyndromal symptoms experienced by normal con-
trols, unmedicated patients with bipolar disorder or pa-
tients with other mood disorders is not known. Finally, 
understanding the pattern of subsyndromal mood symp-
toms is not intended to blur the critical diagnostic con-
cept of bipolarity  [79] .
 Conclusion 
 There is a need to standardize the definition of sub-
syndromal mood symptoms in bipolar disorder and to 
validate approaches for measuring them. Future studies 
of maintenance agents in bipolar disorder should con-
sider the daily symptom load, regardless of the study de-
sign. For some patients, subsyndromal mood symptoms 
that do not respond to treatment may be as deleterious as 
an acute episode that responds to treatment. The goal of 
maintenance therapy for bipolar disorder is not just to 
increase the time to the next episode, but also to improve 
daily symptom burden and allow patients to return to 
everyday functioning. Measures of subsyndromal symp-
tom load should become important adjunctive measures 
to traditional measures, as future approaches shift away 
from the prevention of episodes towards achieving a lev-
el of daily disease activity that allows the patient an ac-
ceptable quality of life. With the availability of newer 
agents for maintenance treatment, the degree of relief 
provided from subsyndromal symptoms may distinguish 
between therapies and help to individualize treatments. 
As study designs for maintenance therapies for bipolar 
disorder continue to evolve, it is time to include the daily 
symptom burden as an additional measurable outcome.
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